We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

FDA chief Gottlieb ‘names and shames’ big pharma for delaying generic competition

When Dr. Scott Gottlieb, commissioner of the Food and Drug Administration, publicly listed pharmaceutical companies that have “potentially blocked access” to samples of their branded products to generic drug developers — thereby delaying competition — he won praise from many quarters.

Listing the companies that had been the target of complaints by generic manufacturers — “naming and shaming” as it is sometimes referred to — is designed to goad them into reducing “unnecessary hurdles to generic drug development and approval,” Gottlieb said in a statement....

Subscription required to view this article.

This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content

If you do not currently subscribe to FTCWatch please contact us for subscription information:
Email: customerservices@ftcwatch.com
Phone: 202-909-2156

FTCWatch is delivered in the following formats: via email alert and online at mlexwatch.com/ftcwatch